Tilray Brands, Inc. (NASDAQ:TLRY) Given Consensus Rating of "Reduce" by Brokerages

Key Points

• Analysts give Tilray an average recommendation of "Reduce" across seven covering brokers (2 sell, 4 hold, 1 buy), with an average 1‑year price target of $15.00.
• Tilray reported ($0.41) EPS versus a ($0.14) consensus while posting $217.5M in revenue, and the company remains unprofitable with a negative net margin (~251.7%) and a market cap near $1.1B.

Shares of Tilray Brands, Inc. (NASDAQ:TLRY - Get Free Report) have been assigned an average recommendation of "Reduce" from the seven analysts that are presently covering the company, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and one has issued a buy recommendation on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $15.00.

A number of analysts have recently weighed in on TLRY shares. Atb Cap Markets raised shares of Tilray Brands from a "strong sell" rating to a "hold" rating in a report on Wednesday, December 10th. Weiss Ratings restated a "sell (d-)" rating on shares of Tilray Brands in a research report on Wednesday, October 8th. Wall Street Zen raised Tilray Brands from a "strong sell" rating to a "hold" rating in a report on Saturday, October 11th. Finally, Zacks Research cut Tilray Brands from a "hold" rating to a "strong sell" rating in a report on Tuesday, January 13th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in TLRY. Silverlake Wealth Management LLC bought a new stake in shares of Tilray Brands during the 3rd quarter valued at approximately $25,000. Oppenheimer & Co. Inc. acquired a new stake in Tilray Brands in the third quarter valued at approximately $25,000. Unified Investment Management bought a new stake in shares of Tilray Brands during the third quarter worth $26,000. J.W. Cole Advisors Inc. grew its stake in shares of Tilray Brands by 203.2% during the second quarter. J.W. Cole Advisors Inc. now owns 71,890 shares of the company's stock worth $30,000 after buying an additional 48,177 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new position in shares of Tilray Brands during the third quarter worth $30,000. Institutional investors own 9.35% of the company's stock.

Tilray Brands Price Performance

Shares of NASDAQ TLRY opened at $9.45 on Tuesday. The business has a fifty day moving average price of $9.73 and a two-hundred day moving average price of $10.84. The stock has a market capitalization of $1.10 billion, a PE ratio of -0.43 and a beta of 1.77. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.81 and a quick ratio of 1.72. Tilray Brands has a fifty-two week low of $3.51 and a fifty-two week high of $23.20.

Tilray Brands (NASDAQ:TLRY - Get Free Report) last issued its quarterly earnings results on Thursday, January 8th. The company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.27). Tilray Brands had a negative return on equity of 6.35% and a negative net margin of 251.69%.The company had revenue of $217.51 million during the quarter, compared to the consensus estimate of $211.15 million. During the same quarter in the previous year, the business posted ($0.03) EPS. As a group, equities analysts predict that Tilray Brands will post -0.2 earnings per share for the current fiscal year.

Tilray Brands Company Profile

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray's product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.